Europe Addresses Antibiotic Resistance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Europe Addresses Antibiotic Resistance


Pharmaceutical Technology Europe
Volume 22, Issue 12

In summary

Antibiotic resistance remains a very serious threat due to the limitations of current agents and poor public knowledge about bacterial infections. The European Antibiotic Awareness Day campaign represents a continuing effort to combat these problems across the region, but measures are also needed to boost new pharmaceutical industry R&D efforts. Although the 2009 European Observatory on Health Systems and Policies report was a welcome step forward in summarising thinking of how to stimulate new industry research, it has not yet prompted governments to implement specific incentives. In 2009, a survey among European intensive care physicians found that 53% had treated at least one patient infected with a bacterium totally or almost totally resistant to available antibiotics during the previous 6 months.10 Worrying developments such as these are a warning that governments must bring a sense of urgency to incentivising new antibiotic R&D efforts.

References

1. About European Antibiotic Awareness Day (2008). antibiotic2008.ecdc.europa.eu

2. The overuse of antibiotics — Eurobarometer statistics. http://efpia.blogspot.com/

3. E. Mossialos, et al., Policies and incentives for promoting innovation in antibiotic research (2010). http://www.euro.who.int/

4. Antimicrobial Resistance, Eurobarometer 72.5 (2009). ec.europa.eu

5. Les Antibiotiques, Eurobarometer Special (2003). ec.europa.eu

6. C.A.M. McNulty, J. Antimicrob. Chemo., 65,1526-1533 (2010).

7. S. Coenen, et al., Acta Clinica Belgica, 63-5 (2008).

8. B. Huttner. Antibiotics Are Not Automatic Anymore — The French National Campaign To Cut Antibiotic Overuse. PLoS Medicine 6(6) (2009). http://www.plosmedicine.org/

9. L. Jarvis, An Uphill Battle (2008). http://pubs.acs.org/cen/

10. A. Lepape, Eurosurveillance, 14(45), 12 (2009). http://www.eurosurveillance.org/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology Europe,
Click here